Table 1.
Clinicopathological parameters and survival of 144 metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor (EGFR) (mAb) cetuximab or panitumumab. Progression free survival (PFS) and overall survival (OS) relative to the indicated features were determined by Kaplan–Meier analysis and the log-rank test. p-Value of ≤0.05 was considered significant.
| Characteristics | Number of Patients (%) | PFS in Months (Mean ± SE) | 95% CI | p-Value | OS in Months (Mean ± SE) | 95% CI | p-Value |
|---|---|---|---|---|---|---|---|
| Age in years | NS | NS | |||||
| ≤70 | 85 (59) | 53.7 ± 5.8 | 42.3–65.1 | 61.5 ± 4.6 | 52.5–70.6 | ||
| >70 | 59 (41) | 55.5 ± 5.6 | 44.4–66.5 | 67.6 ± 4.7 | 58.3–76.9 | ||
| Gender | NS | NS | |||||
| Male | 101 (70) | 47.1 ± 4.4 | 38.5–55.6 | 63.8 ± 3.2 | 57.4–70.1 | ||
| Female | 43 (30) | 71.9 ± 7.0 | 58.1–85.6 | 59.4 ± 6.6 | 46.4–72.4 | ||
| Tumour Type | NS | NS | |||||
| Resection | 76 (53) | 52.9 ± 6.0 | 41.2–64.6 | 63.2 ± 4.1 | 55.1–71.3 | ||
| Liver Metastasis | 11 (8) | 39.14 ± 8.7 | 22.4–56.1 | 64.1 ± 5.5 | 53.3–74.9 | ||
| Biopsy | 57 (39) | 48.4 ± 4.8 | 39.0–57.8 | 61.4 ± 6.5 | 48.5–74.2 | ||
| T stage * | NS | NS | |||||
| <T4 | 46 (32) | 51.2 ± 6.9 | 37.5–64.9 | 63.8 ± 4.9 | 54.2–73.4 | ||
| T4 | 33 (23) | 38.8 ± 4.2 | 30.6–47.0 | 61.7 ± 6.6 | 48.9–74.6 | ||
| N Stage * | NS | NS | |||||
| <N2 | 41 (29) | 50.5 ± 6.4 | 38.1–62.9 | 63.9 ± 4.3 | 55.6–72.3 | ||
| N2 | 38 (26) | 63.3 ± 7.8 | 48.0–78.5 | 65.1 ± 11.3 | 43.0–87.2 | ||
| M Stage * | NS | NS | |||||
| Mx/M0 | 70 (49) | 53.6 ± 6.1 | 41.5–65.6 | 64.7 ± 4.1 | 56.6–72.8 | ||
| M1 | 11 (8) | 25.8 ± 4.1 | 17.8–33.8 | 34.8 ± 3.0 | 28.9–40.7 | ||
| Vascular Invasion * | NS | NS | |||||
| V0 | 30 (21) | 49.7 ± 7.6 | 34.8–64.7 | 63.6 ± 5.7 | 52.3–74.8 | ||
| V1 | 49 (34) | 54.7 ± 7.1 | 40.8–68.7 | 65.5 ± 5.9 | 53.9–77.0 | ||
| LVI * | NS | NS | |||||
| Yes | 39 (27) | 55.5 ± 7.8 | 40.2–70.7 | 64.6 ± 4.9 | 54.8–74.4 | ||
| No | 39 (27) | 50.1 ± 6.7 | 37.1–63.2 | 63.6 ± 6.4 | 51.1–76.1 | ||
| Grade * | 0.022 | NS | |||||
| G1&G2 | 78 (54) | 61.3 ± 6.1 | 49.4–73.1 | 63.0 ± 4.1 | 54.9–71.1 | ||
| G3 | 32 (22) | 31.9 ± 6.4 | 19.4–44.6 | 57.7 ± 6.2 | 45.4–69.9 | ||
| Apical Node * | NS | NS | |||||
| Negative | 67 (47) | 53.4 ± 6.2 | 41.2–65.5 | 65.5 ± 4.1 | 56.4–72.7 | ||
| Positive | 12 (8) | 30.4 ± 4.4 | 21.9–38.9 | 36.7 ± 2.6 | 31.6–41.7 | ||
| Chemotherapy | NS | 0.007 | |||||
| FOLFOX + cetuximab | 25 (17) | 45.8 ± 5.9 | 34.2–57.6 | 47.6 ± 6.5 | 34.8–60.5 | ||
| FOLFIRI + cetuximAb | 78 (54) | 36.4 ± 3.7 | 29.1–43.6 | 65.5 ± 3.6 | 58.5–72.5 |
* data for T stage, N stage, Vascular invasion, and grade missing in some cases due to being biopsy and/or liver metastases patients. OS and PFS analysis were conducted by omitting the missing data.